Trial Profile
A Pilot Study of Brain Irradiation and Tremelimumab in Metastatic Breast Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Aug 2022
Price :
$35
*
At a glance
- Drugs Tremelimumab (Primary) ; Durvalumab
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 15 Jul 2021 Status changed from active, no longer recruiting to completed.
- 16 Jul 2020 Planned End Date changed from 1 Sep 2020 to 1 Sep 2021.
- 16 Jul 2020 Planned primary completion date changed from 1 Sep 2020 to 1 Sep 2021.